Amylyx Pharmaceuticals, Inc. (AMLX)
27.79
-0.29
(-1.03%)
USD |
NASDAQ |
Oct 02, 16:00
27.80
+0.01
(+0.04%)
After-Hours: 20:00
Amylyx Pharmaceuticals Enterprise Value : 2.849B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 2.849B |
| October 01, 2026 | 2.882B |
| September 30, 2026 | 2.995B |
| September 29, 2026 | 3.015B |
| September 28, 2026 | 3.079B |
| September 25, 2026 | 3.039B |
| September 24, 2026 | 3.111B |
| September 23, 2026 | 3.163B |
| September 22, 2026 | 3.430B |
| September 21, 2026 | 3.362B |
| September 18, 2026 | 3.364B |
| September 17, 2026 | 3.534B |
| September 16, 2026 | 3.388B |
| September 15, 2026 | 3.446B |
| September 14, 2026 | 3.501B |
| September 11, 2026 | 3.276B |
| September 10, 2026 | 3.328B |
| September 09, 2026 | 3.363B |
| September 08, 2026 | 3.528B |
| September 04, 2026 | 3.552B |
| September 03, 2026 | 3.537B |
| September 02, 2026 | 3.596B |
| September 01, 2026 | 3.520B |
| August 31, 2026 | 3.513B |
| August 28, 2026 | 3.623B |
| Date | Value |
|---|---|
| August 27, 2026 | 3.895B |
| August 26, 2026 | 3.884B |
| August 25, 2026 | 3.926B |
| August 24, 2026 | 4.003B |
| August 21, 2026 | 4.060B |
| August 20, 2026 | 4.171B |
| August 19, 2026 | 4.053B |
| August 18, 2026 | 3.665B |
| August 17, 2026 | 2.141B |
| August 14, 2026 | 2.163B |
| August 13, 2026 | 2.258B |
| August 12, 2026 | 2.355B |
| August 11, 2026 | 2.386B |
| August 10, 2026 | 2.279B |
| August 07, 2026 | 2.296B |
| August 06, 2026 | 2.448B |
| August 05, 2026 | 2.188B |
| August 04, 2026 | 2.190B |
| August 03, 2026 | 2.001B |
| July 31, 2026 | 2.016B |
| July 30, 2026 | 2.065B |
| July 29, 2026 | 1.952B |
| July 28, 2026 | 1.932B |
| July 27, 2026 | 1.925B |
| July 24, 2026 | 1.805B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pfizer Inc. | 210.23B |
| Eli Lilly & Co. | 1.122T |
| Merck & Co., Inc. | 403.00B |
| EyePoint, Inc. | 118.09M |
| Bristol Myers Squibb Co. | 158.92B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.42M |
| Total Expenses (Quarterly) | 43.42M |
| EPS Diluted (Quarterly) | -0.3905 |
| Earnings Yield | -5.16% |
| Normalized Earnings Yield | -5.156 |